Retagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus to help regulate blood glucose levels by increasing incretin activity, which enhances insulin… Read more
Retagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus to help regulate blood glucose levels by increasing incretin activity, which enhances insulin secretion. The compounds listed in this category, including Retagliptin API, associated process and degradation impurities, and stable isotope-labelled standards, serve as critical tools for pharmaceutical analysis. Laboratory professionals rely on these high-quality materials for impurity profiling, the validation of analytical methods such as HPLC or LC-MS, and ongoing quality control testing throughout the drug development lifecycle. By utilizing these precise reference materials, researchers can accurately identify and quantify potential impurities or metabolites, ensuring compliance with rigorous regulatory standards for drug safety and efficacy.